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ABBREVIATIONS
CoQ10 Coenzyme Q10
GAMT Guanidinoacetate methyl transferase
IEM Inborn error of metabolism
MoCoF Molybdenum cofactor
NCL Neuronal ceroid lipofuscinosis
PDE Pyridoxine-dependent epilepsy
PLP Pyridoxal 5¢-phosphate
PNPO Pyridox(am)ine 5¢-phosphate oxidase
SUOX Sulphite oxidase
Seizures may be the first and the major presenting feature of an inborn error of metabolism (IEM),
for example in a neonate with pyridoxine-dependent epilepsy. In other IEMs, seizures may be pre-
ceded by other major symptoms: by a reduced level of consciousness in a child with an organic
acidaemia or urea cycle defect; or by loss of skills, progressive weakness, ataxia, and upper motor
signs in a child with a lysosomal storage disorder or peroxisomal leukodystrophy. This review
concentrates on those IEMs for which specific treatment is available. The commonmetabolic
causes of seizures vary according to the age at presentation. Features from the history,
examination, imaging, and first line biochemical investigations can all provide clues to an inborn
error. This review attempts to delineate these and to provide a guide to the specific tests that can
be used tomake the diagnosis of disorders with specific treatment.
Inborn errors of metabolism (IEMs) are a relatively infrequent
cause of epilepsy, but their recognition is of paramount impor-
tance because many of these conditions are treatable, particu-
larly those presenting in the neonatal period and in early
infancy. Many biochemical and genetic investigations are
requested by practising clinicians because of the imperative of
not missing a treatable cause of the early onset epileptic
encephalopathies. This review is timely because the genetic
basis of several treatable metabolic epilepsies has been estab-
lished in recent years, and experimental treatments are being
developed and trialled in some conditions that were previously
considered to be untreatable. These treatments include vita-
min supplementation, provision of alternative substrates (to
bypass a block), and dietary manipulation.
An epileptic seizure has been defined by the International
League Against Epilepsy and International Bureau for
Epilepsy as a ‘transient occurrence of signs and ⁄or symptoms
due to abnormal excessive or synchronous neuronal activity
in the brain’.1 The same groups defined epilepsy as ‘a disor-
der of the brain characterized by an enduring predisposition
to generate epileptic seizures and by the neurobiological,
cognitive, psychological, and social consequences of this con-
dition’. Although epilepsy is common, affecting at least 0.5%
of the population,2 the precise prevalence of metabolic epi-
lepsies is unknown, but they are likely to represent a small
minority of all causes of epilepsy. However, seizures are a
frequent symptom in metabolic disease, having been
reported in more than 200 different IEMs, and seizures are a
relatively common reason for referral to the metabolic paedi-
atrician or biochemical geneticist. Furthermore, although
IEMs are rarely the cause of epilepsy, it is important to
recognize and diagnose this group of disorders, since they
may be treatable, and there are significant implications for
genetic counselling.
The classification of metabolic epilepsies is difficult.
Seizures may be characterized by their semiology and electro-
encephalographic (EEG) features, although epilepsies in IEMs
are associated with multiple, usually generalized, seizure types.
The most recent International League Against Epilepsy Com-
mission on Classification and Terminology proposes ‘struc-
tural ⁄metabolic’ as an aetiology group for conditions or
diseases that have been demonstrated to be associated with a
substantially increased risk of developing epilepsy, including
disorders of genetic origin.3 A more practical way of consider-
ing the metabolic epilepsies is by age at presentation (Table I),
and in this review we consider those epilepsies that present in
the neonatal period and first 6 months of life; those that more
often present in late infancy and early childhood; and, finally,
metabolic epilepsies presenting in later childhood and
adolescence. There is, of course, considerable overlap between
these groups. We recently reviewed mitochondrial epilepsies
in a companion article in this journal,4 and so will not discuss
them in great detail here, but will indicate which mitochon-
drial epilepsies may present at particular ages.
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The large number of IEMs associated with epilepsy may be
explained by the plethora of different disease mechanisms that
may trigger seizures. In some patients electrolyte disturbance
may lead to seizure generation, particularly in disorders associ-
ated with hyponatraemia, hypocalcaemia, or hypomagnesa-
emia. In other cases seizures may occur at times of acute
metabolic decompensation due to hypoglycaemia (e.g. fat oxi-
dation disorders, glycogen storage diseases, and disorders of
gluconeogenesis) or hyperammonaemia (e.g. urea cycle dis-
orders or organic acidaemias). Other pathogenic mechanisms
associated with seizure generation include deficiency of a vita-
min or cofactor (such as pyridoxal phosphate, 5-methyltetra-
hydrofolate, biotin, or coenzyme Q10 [CoQ10]), cerebral
energy deficiency (as in glucose transporter defects, disorders
of creatine biosynthesis or transport, and mitochondrial respi-
ratory chain deficiencies), chemical disruption of neurotrans-
mission (ion channel disorders and defects of neurotransmitter
synthesis or recycling), or physical disruption of neural net-
works as a result of brain malformations or IEMs with cerebral
accumulation of abnormal storage material. Finally, seizures
may be triggered by direct neurotoxicity of accumulating
intermediates, as in untreated phenylketonuria.
EPILEPTIC ENCEPHALOPATHY PRESENTING IN THE
NEONATAL PERIOD AND EARLY INFANCY
Seizures occur in 1 in 1000 live births, and the most common
cause is hypoxic–ischaemic encephalopathy. However, some
newborn infants are in a poor condition at birth because they
have an underlying inborn error of metabolism so, if seizures
are persistent and difficult to treat with conventional
antiepileptic drugs (AEDs), the neonatologist should consider
whether hypoxic–ischaemic encephalopathy is the primary
problem or whether there could be an underlying IEM. Clini-
cally, a semiology of infantile spasms or myoclonic seizures,
or, electrographically, hypsarrhythmia or burst suppression,
should always suggest careful consideration of an IEM.
Abnormal intrauterine movements (fluttering or hiccoughs)
can also be a pointer to a metabolic disorder.
Treatable disorders
Pyridoxine-dependent epilepsy
Pyridoxine-dependent epilepsy (PDE) due to antiquitin defi-
ciency (a-amino adipic semialdehyde [a-AASA] dehydrogenase
deficiency; OMIM 266100) is an inborn error of lysine catabo-
lism that results in a secondary deficiency of vitamin B6 due to
adduct formation between D1-piperideine-6-carboxylate and
pyridoxal 5¢-phosphate (PLP), the active form of vitamin B6 in
humans.5,6 Patients with this disorder typically present in the
first days of life with a severe seizure disorder that is resistant
to treatment with conventional anticonvulsant medications
but responsive to treatment with pyridoxine. Often the infant
is in poor condition at delivery and the seizure disorder may
be accompanied by multisystem symptomatology such as met-
abolic acidosis, electrolyte disturbance, abdominal distension,
and feed intolerance, resulting in misdiagnosis as hypoxic–is-
chaemic encephalopathy or sepsis.7 Frequent multifocal and
generalized myoclonic jerks are observed in PDE, often inter-
mixed with tonic symptoms, abnormal eye movement, grimac-
ing, or irritability.8
Although in most instances PDE responds quickly and
completely to pyridoxine, any child with a resistant epileptic
encephalopathy should undergo an adequate treatment trial
of vitamin B6 (see recommended doses below) accompanied
Table I: Classification of metabolic epilepsies according to age at presentation
Neonatal period to early infancy Late infancy to early childhood Late childhood to adolescence
PDE Creatine synthesis defects CoQ10 deficiency
PNPO deficiency Infantile and late infantile NCL Lafora body and Unverricht–Lundborg disease
Folinic acid responsive seizures Mitochondrial disorders (Alpers
syndrome and others)
MERRF
Biotinidase deficiency Sialidosis MELAS
GLUT1 deficiency Gangliosidosis POLG-related disease: MIRAS, SCAE, MEMSA
Non-ketotic hyperglycinaemia Milder variants of PDE and PNPO
deficiency
Juvenile NCL
Serine biosynthesis defects Congenital disorders of
glycosylation
Late onset GM2 gangliosidosis
(Sandhoff, Tay–Sachs)
Molybdenum cofactor and sulphite oxidase
deficiencies
Gaucher type III
Menkes disease Niemann–Pick type C
Disorders of peroxisome biogenesis and b-oxidation Peroxisomal disorders
Congenital disorders of glycosylation
Cathepsin D deficiency (congenital NCL)
PDE, pyridoxine-dependent epilepsy; CoQ10, coenzyme Q10; PNPO, pyridox(am)ine 5¢-phosphate oxidase; MERRF, myoclonic epilepsy with
ragged-red fibres; MELAS, mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes; GLUT1, glucose transporter across the blood–
brain barrier; POLG, gene encoding catalytic subunit of DNA polymerase gamma; MIRAS, mitochondrial recessive ataxia syndrome; SCAE,
spinocerebellar ataxia with epilepsy; MEMSA, myoclonus, epilepsy, myopathy, sensory ataxia; NCL, neuronal ceroid lipofuscinosis.
What this paper adds
• This paper provides a concise summary of the major inborn errors of metabolism
(IEMs) which may present with epilepsy, categorized by age at presentation.
• An overview of key clinical, biochemical, and genetic diagnostic features to aid
differential diagnosis is presented.
• Most importantly, this article emphasizes the treatable IEMs causing epilepsy
and provides information about appropriate medications, doses, and routes of
administration.
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by EEG recording, as some patients do not show a dramatic
initial response, probably because of multiple contributing
pathologies. Treatment should initially be commenced in an
intensive care setting as these infants are vulnerable to
apnoea, profound hypotonia, and hypotension. Following a
single 100mg dose of intravenous pyridoxine, seizures will
usually stop, and our practice is to follow this up with a
maintenance dose of 5 to 15mg ⁄kg ⁄day in two divided doses;
however, higher doses (15–30mg ⁄kg ⁄d) have been recom-
mended by an international study group.9 Seizures, which
are of multiple types in children with PDE, will respond to
both pyridoxine and PLP, although pyridoxine tends to be
used as the first-line treatment in the UK as there is more
experience of its use and it is available in both intravenous
and oral formulations. Pyridoxine treatment has been associ-
ated with peripheral neuropathy; thus, annual monitoring of
nerve conduction is recommended in children who can coop-
erate. Clinicians should aim to reduce pyridoxine to the low-
est effective dose if there is any evidence of abnormality on
neurophysiological testing or clinical symptoms. Our experi-
ence suggests that, to minimize the risk of neuropathy, in
most cases treatment with pyridoxine should not exceed a
total daily dose of 200mg in children.
Diagnostic confirmation of PDE is by measurement of ele-
vated a-AASA in urine and ⁄or plasma and cerebrospinal fluid
(CSF). This can be done while the child is taking vitamin B6
and thus should not delay commencement of treatment. Other
investigations which may be suggestive of the diagnosis
include plasma and CSF amino acids, CSF monoamine
metabolites, and CSF PLP (Table II). PDE should also be
considered in children who show an initial response to AEDs
but subsequently become drug resistant, as they may represent
the atypical later-onset group.
In the long term, treated children with PDE remain seizure-
free, although some have breakthrough fits during periods of
intercurrent infection and fever.7 In some children it has
proved helpful to double the regular dose of pyridoxine during
the first few days of a febrile illness to prevent seizures. Mild
to moderate learning difficulty is common, with speech and
language development being particularly impaired.
Pyridox(am)ine 5 ¢-phosphate oxidase deficiency
Pyridox(am)ine 5¢-phosphate oxidase (PNPO) is essential for
the synthesis of PLP.6 Deficiency of this enzyme (OMIM
610090) has been described in only a small number of families
worldwide and typically results in a severe neonatal seizure
disorder which responds to treatment with PLP. Often infants
with PNPO deficiency are born preterm and there may be a
family history of infertility and recurrent miscarriage. Seizures
are similar to those seen in PDE, with prolonged episodes of
mixed multifocal myoclonic–tonic symptoms often associated
with grimacing and abnormal eye movements.8 Alongside
clinical clues and an EEG burst suppression pattern, diagnosis
of this disorder is suggested by secondary changes in plasma
and CSF amino acids, together with reduced CSF PLP and
monoamine metabolites (Table II). The diagnosis may be
confirmed by mutation analysis of the PNPO gene.10
Outcome in the first described cases was poor, with a high
mortality in the first weeks of life. However, increased aware-
ness of the disorder and prompt diagnosis has subsequently
revealed an expanded phenotype, with some children present-
ing with a comparatively mild seizure disorder beyond the
neonatal period and some surviving into adulthood.
Treatment is with PLP, which is currently available in an
oral formulation only; doses between 10 and 30mg ⁄kg ⁄day in
divided doses have been successful in controlling seizures. As
with initiation of pyridoxine treatment, the first doses of PLP
should be given in an intensive care setting because of the risk
of respiratory and cardiovascular collapse. In the long term it
is recommended that children on PLP be monitored with liver
ultrasonography and liver function tests. This is based on the
observation that PLP treatment has been associated with liver
damage in a single patient with PNPO deficiency (it has not
been firmly established that PLP, or the specific formulation
of PLP, was responsible for the patient’s liver damage). Prena-
tal diagnosis of PNPO deficiency has been undertaken, and
parents who had previously lost a child as a result of severe
neonatal epileptic encephalopathy opted for termination
(unpublished observation); in theory, prenatal treatment
would be an alternative but there are no data on the outcome
of this approach.
Folinic acid-responsive seizures
Folinic acid-responsive seizures were first described in a group
of neonates with onset of seizures (myoclonic or clonic) in the
first 5 days of life, associated with irritability and white matter
abnormalities on brain magnetic resonance imaging (MRI).
These infants also shared a characteristic unidentified ‘peak’
on the CSF high-performance liquid chromatogram and all
responded, to a variable degree, to folinic acid. Subsequently,
other infants fulfilling these criteria have been identified whose
seizures responded to pyridoxine and who have been diag-
nosed with antiquitin deficiency, with elevated a-AASA and
pathogenic mutations in the antiquitin gene. Thus, folinic
acid-responsive seizures and PDE due to antiquitin deficiency
are now understood to be biochemically and genetically iden-
tical. The ‘peak’ on high-performance liquid chromatogram
remains unidentified.9,11
Multiple carboxylase deficiency due to biotinidase or
holocarboxylase synthetase deficiency
Both inherited disorders, biotinidase deficiency (OMIM
253260) and holocarboxylase synthetase (HCS) deficiency
(253270), affect the vital coenzyme function of biotin. This
results in reduced activity of all four biotin-dependent carbox-
ylases (acetyl-CoA carboxylase, pyruvate carboxylase, propio-
nyl-CoA carboxylase, and 3-methylcrotonyl-CoA carboxylase)
and a clinical picture characterized by neurological disease
including seizures, often infantile spasms.12 Other typical
symptoms include ataxia, hypotonia, encephalopathy, and skin
manifestations including alopecia and a generalized or perioral
eczematous rash. Age at presentation is extremely variable, as
is the pattern of symptoms; however, many patients present in
the first months of life. Biochemical investigation in symptom-
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Table II: Investigation of metabolic epilepsies
Investigation Abnormality Disorder
Routine clinical chemistry
Glucose Low Fat oxidation disorders
Glycogen storage diseases
Disorders of gluconeogenesis
Calcium Low Disorders of calcium homeostasis
Renal tubulopathy
PDE
Magnesium Low Disorders of magnesium transport
Renal tubulopathy
PDE
Ammonia High Urea cycle disorders
Organic acidaemias
Lactate High PDHc deficiency
Mitochondrial respiratory chain defects
Biotinidase deficiency
Lipoic acid synthetase deficiency
Liver function Abnormal May suggest Alpers or another
hepatocerebral mtDNA depletion syndrome
Disorders of N-glycosylation
Creatine kinase High Dystroglycanopathies
Specialised investigations in blood
Plasma amino acids High glycine NKH; Lipoic acid synthetase deficiency
High glycine and threonine PNPO deficiency; PDE
Low serine Serine biosynthesis disorders
Low glutamine Glutamine synthase deficiency
High phenylalanine Untreated phenylketonuria
High proline Hyperprolinaemia type II
Urate Low MoCoF deficiency
Copper and caeruloplasmin Low Menkes syndrome
Plasma VLCFA High Zellweger syndrome
Other peroxisomal disorders
Pristanic acid High Alpha methyl-acyl-CoA racemase deficiency
Plasma biotinidase activity Low Biotinidase deficiency
Serum transferrin isoelectric focusing Abnormal transferrin glycoforms Congenital disorders of glycosylation
White cell CoQ10 Low Disorders of CoQ10 biosynthesis; secondary
deficiency in somemitochondrial disorders
Vacuolated lymphocytes Present Lysosomal storage disorders, including late
infantile and juvenile NCL
Metabolic investigations in urine
Organic acids Vanillactate PNPO deficiency
Specific organic acids Organic acidaemias, e.g. D and L-2-hydroxyglutaric
acidurias, cobalamin C deficiency (form of
methylmalonic aciduria); biotinidase ⁄HCS
deficiencies
Krebs cycle intermediates Krebs cycle disorders; mitochondrial respiratory
chain defects
Sulphite and sulphocysteine High SUOX deficiency
MoCoF deficiency
Guanidinoacetic acid High GAMT deficiency
Low AGAT deficiency
Creatine Low GAMT and AGAT deficiencies
High Creatine transporter deficiency
Alpha-aminoadipic semialdehyde High PDE; MoCoF and SUOX deficiencies
Purine ⁄pyrimidine screen Hypoxanthine MoCoF deficiency
Succinyladenosine Adenylosuccinate lyase deficiency
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atic patients usually shows lactic acidosis and a characteristic
organic aciduria, although some patients do not have these
features present.13 Diagnosis is confirmed by measurement of
serum enzyme activity in biotinidase deficiency and by muta-
tional analysis or lymphocyte or fibroblast carboxylase activity
in HCS deficiency. Screening of newborn infants for biotini-
dase deficiency is performed in some countries.12
All patients with biotinidase deficiency and most with HCS
deficiency respond excellently to oral biotin. Delay in treatment
will result in irreversible neurological disease; thus, a treatment
trial of 5 to 10mg oral biotin daily is justified in any child with
an unexplained neurological disorder including seizures, pend-
ing confirmatory diagnostic investigations. This is particularly
true in unscreened populations such as in theUK.14
GLUT1 deficiency syndrome
GLUT1 is a membrane transporter that facilitates glucose
transport across the blood–brain barrier. Defective GLUT1
(OMIM 606777) results in cerebral deficiency of glucose, the
vital source of energy for brain metabolism, and a low CSF
glucose concentration. The phenotype of this IEM is expand-
ing with classical early onset seen before 2 years of age, later
onset between 2 and 10 years, and a non-classical form with
mental retardation* and movement disorder but no epi-
lepsy.15,16 Familial transmission has been reported. In classical
early-onset GLUT1 deficiency the neonatal period may be
normal and breastfeeding may be protective. Seizures are the
main presenting symptom, with 79% of all first seizures occur-
ring in the first 6 months of life. Semiology is often of cya-
notic attacks or of eye movement seizures which may be
mistaken for opsoclonus–myoclonus. The interictal EEG may
be normal. The ictal EEG may show focal slowing or
discharges, including 2.5 to 4 Hz spike and wave. A striking
difference between pre- and postprandial EEG may be seen,
with a decrease in epileptic discharges following carbohydrate
intake. GLUT1 deficiency is now known to be a cause of
drug-resistant childhood absence epilepsy and of adult-onset
absence epilepsy with a normal CSF glucose.
A lumbar puncture, preferably while fasting, to demonstrate
hypoglycorrhacia is the first step in diagnosis. CSF glucose is
typically less than 2.5mmol ⁄L, although values greater than
this have been reported. The ratio of CSF to plasma glucose
is particularly important, so a non-stressed (again, preferably,
fasting) plasma glucose should be taken before the lumbar
puncture. In the absence of central nervous system (CNS)
infection, a CSF to blood ratio of less than 0.5 is diagnostic.
CSF lactate is normal or low. The degree of hypoglycorrhacia
and absolute ‘cut-off’ for a diagnosis of GLUT1 deficiency
remain a source of debate, and mild clinical phenotypes have
been reported with normoglycorrhacia and a normal CSF to
blood glucose ratio; thus molecular genetic analysis of
the SLC2A1 gene is considered the standard criterion for
diagnosis.16 Approximately 80% of patients harbour patho-
genic mutations. As GLUT1 is the predominant glucose
transporter in red blood cells, reduced erythrocyte glucose
uptake may also be indicative of reduced glucose transport
into the CNS. However, this investigation is not routinely
available and may give false-negative results in mild cases.17
Table II: Continued
Investigation Abnormality Disorder
Investigations in CSF (with paired blood sample)
Glucose Low CSF: blood glucose ratio <0.4 GLUT1 defect
Lactate High Mitochondrial respiratory chain disorder
PDHc deficiency
Amino acids High glycine CSF: plasma glycine
ratio >0.06 (normal <0.04)
NKH
Low serine Disorders of serine biosynthesis
High threonine and glycine PNPO deficiency, PDE
Pyridoxal 5¢-phosphate Low PNPO deficiency, PDE




May be low in serine biosynthesis disorders and
methylene tetrahydrofolate reductase deficiency
Neurotransmitter amine
metabolites (HVA and 5-HIAA)
Low PNPO deficiency, PDE
3-Methoxytyrosine High PNPO deficiency, PDE
PDE, pyridoxine-dependent epilepsy; PDHc, pyruvate dehydrogenase complex; mtDNA, mitochondrial DNA; NKH, non-ketotic hyperglycinaemia;
PNPO, pyridox(am)ine 5¢-phosphate oxidase; VLCFA, very long-chain fatty acid; CoQ10, coenzyme Q10; NCL, neuronal ceroid lipofuscinosis; HCS,
holocarboxylase synthetase; SUOX, sulphite oxidase; MoCoF, molybdenum cofactor; GAMT, guanidinoacetate methyl transferase; AGAT,
arginine–glycine amidinotransferase; CSF, cerebrospinal fluid; GLUT1, glucose transporter across the blood–brain barrier; HVA, homovanillic
acid; 5-HIAA 5-hydroxy indoleacetic acid.
*UK usage: learning disability
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Epilepsy in GLUT1 deficiency is drug resistant and may be
aggravated by fasting and by AEDs that inhibit GLUT1
(phenobarbitone, valproate, diazepam). GLUT1 deficiency is
eminently treatable with the ketogenic diet, which should be
commenced at the earliest opportunity and continued until at
least adolescence, when the energy demands of the brain
decrease. This high-fat, low-carbohydrate diet provides an
alternative source of energy for the brain as ketone bodies,
which are produced in the liver and which can easily penetrate
the blood–brain barrier. In the vast majority of patients the ke-
togenic diet is successful at controlling seizures, allowing with-
drawal of AEDs.18 Seizures are controlled at lower blood levels
of b-hydroxybutyrate than are needed to nourish the brain.
Organic acidurias, aminoacidopathies, and urea cycle
defects
In general, these disorders give rise to episodes of acute
encephalopathy in which seizures may occur as brain intoxica-
tion progresses. There are usually associated features of
systemic metabolic decompensation such as acidosis, ketonuria,
and hyperammonaemia. Diagnosis is made on the basis of
analysis of urine organic acids, blood spot acylcarnitine profile,
and plasma and urine amino acids. A discussion of the treat-
ment of these disorders is beyond the scope of this review, but
many specific forms of treatment are available and if instituted
early will prevent death and severe neurological damage.
Disorders with novel ⁄experimental therapies
Non-ketotic hyperglycinaemia (neonatal type)
The typical neonatal form of non-ketotic hyperglycinaemia
(OMIM 605899) presents within the first days of life following
an apparently symptom-free period. A severe clinical picture
evolves that is characterized by seizures, lethargy, encephalop-
athy, profound hypotonia, and hiccoughs. Respiration
becomes irregular, often progressing to apnoea necessitating
ventilation. EEG usually shows a burst suppression pattern
which, in combination with the clinical features, is very sug-
gestive of the diagnosis. Some patients have structural brain
abnormalities on MRI, including dysgenesis of the corpus
callosum and gyral abnormalities.19
This devastating disorder is caused by a defective glycine
cleavage protein, which is a multienzyme complex that
degrades glycine in the CNS. If the diagnosis is suspected,
plasma and CSF amino acids should be measured and will
reveal grossly elevated glycine, in particular an increased CSF
to plasma ratio.20 It should be noted that sodium valproate
therapy may also lead to increased glycine levels, although
usually to a far lesser degree than is observed in non-ketotic
hyperglycinaemia.20
Untreated, the neonatal form of non-ketotic hyperglycina-
emia is associated with death in the first months of life.20
Therapy with sodium benzoate and dextromethorphan may
be helpful in some milder forms of the disease, alongside
AEDs and general supportive care.21 The epilepsy remains
drug resistant, infantile spasms may emerge, and the EEG
evolves to hypsarrhythmia or multifocal discharges on a back-
ground without normal activity.
Serine biosynthesis defects
Seizures are a major feature of the clinical presentations of
both 3-phosphoglycerate dehydrogenase deficiency (OMIM
601815) and phosphoserine aminotransferase deficiency
(OMIM 610936).22,23 Microcephaly is present at birth or
acquired in early infancy. Infants are hypertonic and show
severe developmental delay. The epilepsy is often character-
ized by infantile spasms and EEG hypsarrhythmia, and sub-
sequent evolution to a Lennox–Gastaut syndrome has been
reported.24 CSF amino acids should be analyzed after a 6-
hour fast and in affected individuals show a low concentra-
tion of serine, often with a low glycine. Concentrations of
these amino acids may also be low in plasma. To control
seizures and improve the outcome, treatment with serine
(usually together with glycine) must be started soon after
birth. The best outcome with 3-phosphoglycerate dehydro-
genase deficiency has been achieved when an affected infant
was treated in utero.25 A more recent report described two
siblings with a milder clinical phenotype of late childhood-
onset absence epilepsy with typical EEG 3 Hz spike–wave
complexes, who had learning difficulties but normal head
circumference.26
Molybdenum cofactor and sulphite oxidase deficiencies
Molybdenum is an essential cofactor for three enzymes in
humans: xanthine dehydrogenase, sulphite oxidase, and alde-
hyde oxidase. Patients with molybdenum cofactor (MoCoF)
deficiency (OMIM 252150) are deficient in the activity of all
three enzymes; the clinical phenotype is characterized by a
severe seizure disorder with onset in the first days of life, with
dystonia and developmental delay, and the disease usually
results in death in early childhood.27 Equally, seizures may be
absent and the movement disorder mistaken for epilepsy,
AEDs being symptomatically useful for either. Burst suppres-
sion may be seen on the EEG. The underlying disease process
is poorly understood; however, toxic accumulation of endo-
genous sulphite is the most likely pathogenic mechanism. A
suspected diagnosis is confirmed by finding reduced plasma
urate, the presence of sulphite or sulphocysteine in the urine,
and a characteristic urinary purine profile in which uric acid is
replaced by xanthine.28 Hypohomocystinaemia has also been
reported in some cases.29 Isolated sulphite oxidase (SUOX)
deficiency (OMIM 272300) results in an identical clinical
phenotype to MoCoF deficiency and can be differentiated on
the basis of biochemical investigations which, in contrast to
MoCoF deficiency, show normal plasma urate and urinary
purine profile. Genetic confirmation is also possible. Elevated
urinary a-AASA characteristically associated with antiquitin
deficiency, has also recently been described in both MoCoF
and SUOX deficiency.30
Up to two-thirds of patients with MoCoF deficiency have
a proximal defect in the pathway of molybdenum cofactor
synthesis, resulting in the failure to convert GTP to cyclic
pyranopterin monophosphate. This disease type, ‘type A’, is
potentially amenable to a new therapy and should be identi-
fied by mutation analysis of the MOCS1 gene.31 Treatment
of ‘type A’ MoCoF using purified intravenous cyclic
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pyranopterin monophosphate has shown early promise with
a reduction in seizures and improved developmental pro-
gress, as well as correction of biochemical abnormalities.32
However, experience with this experimental treatment is
currently limited to only a few patients. This treatment is
likely to be of benefit only when commenced early in life,
before permanent neurological damage ensues; thus, prompt
diagnosis is of utmost importance, particularly in families
who are known to harbour pathogenic mutations. Further-
more, patients with MoCoF deficiency ‘type B’, who have a
more distal defect in molybdenum cofactor synthesis (mo-
lybdopterin synthase, encoded by MOCS2), will not benefit
from this treatment.
Unfortunately, no definitive treatment is available for
SUOX deficiency, which is managed primarily with supportive
treatment for epilepsy and neurodisability. Attempts at treat-
ment with a diet restricted in sulphur-containing amino acids
(methionine and cysteine) have been largely unsuccessful.33
Menkes disease
Menkes disease (OMIM 309400) is an X-linked recessive dis-
order of copper metabolism that characteristically presents
with seizures and hypotonia in male infants during the first
few months of life. Patients with this neurodegenerative dis-
ease may also encounter clinical problems related to collagen
abnormalities such as vascular tortuosity and bladder divertic-
ulae, which may result in infection. Clinical clues to Menkes
disease include skin laxity, hypothermia, and a particular facial
appearance with ‘sagging’ cheeks and frontal bossing. The
characteristic hair abnormality ‘pili torti’, which is eventually
present in all patients, may also be very helpful in making the
diagnosis.34,35
Copper is essential for the normal functioning of several
copper-containing enzymes, many of which have their action
in the CNS. In Menkes disease, a defective ATP7A protein
results in reduced copper efflux into the circulation from intes-
tinal enterocytes and therefore reduced copper availability for
dependent enzymatic processes. A reduced level of serum cop-
per and serum caeruloplasmin is very suggestive of the diagno-
sis and an abnormal ratio of urinary dopamine to
noradrenaline (indicative of reduced activity of the copper
dependent enzyme, dopamine b-hydroxylase) further supports
this. Mutational analysis of the ATP7A gene is required for
confirmatory diagnosis.36
The electroclinical syndrome has been characterized as
early focal status precipitated by fever with ictal runs of slow
and slow spike–wave posteriorly, evolution to infantile spasms
with modified hypsarrhythmia later in the first year of life and
then, in early childhood, multifocal seizures, tonic spasms, and
myoclonus with multifocal high-amplitude discharges mixed
with slow activity.37
Untreated, Menkes disease is life-limiting, with patients sel-
dom surviving beyond 3 to 4 years. Therapy with subcutane-
ous injections of copper histidine has prolonged life
expectancy in some patients in whom it was started early (first




Neonatal-onset epilepsy that is difficult to control with AEDs
can be a major presenting feature of disorders of peroxisome
biogenesis (Zellweger syndrome; OMIM 214100) and dis-
orders of peroxisomal b-oxidation. An affected newborn infant
is hypotonic, and patients with Zellweger syndrome have char-
acteristic dysmorphic features including large fontanelle, high
forehead, shallow supraorbital ridges, low-set posteriorly
rotated ears, and small chin. The electroretinogram (ERG) is
frequently markedly reduced or absent. Skeletal radiology may
show punctate calcification of cartilage, small renal cysts may
be apparent on ultrasound, and liver function tests may be
abnormal, sometimes with clinical jaundice. Plasma very long
chain fatty acids are elevated. Areas of polymicrogyria are
often frontal or opercular, resulting in a focal EEG and seizure
semiology, and there are often focal motor seizures.38
Neonatal-onset mitochondrial epilepsies
Neonatal-onset seizures are a relatively unusual initial presen-
tation of mitochondrial disease. Neonatal mitochondrial epi-
leptic encephalopathies are usually devastating diseases, often
associated with multiorgan failure. In fact, involvement of
multiple seemingly unrelated organs may alert the clinician to
the possibility of an underlying mitochondrial disorder. These
disorders are typically unresponsive to treatment, with the
possible exception of CoQ10 deficiency (OMIM 607426).
39,40
Infants with RARS2 mutations (OMIM 611523), causing
defective mitochondrial protein synthesis,41 may present with
profound lactic acidosis on the first day of life.42 The lactic
acidosis may subsequently resolve, but the clinical course is
severe, with intractable epilepsy and developmental stasis.
This diagnosis should be suspected in any infant with ponto-
cerebellar hypoplasia on MRI brain scan, particularly if there
is associated lactic acidosis.42
Infants with mutations in SLC25A22 (OMIM 609304),
which encodes the mitochondrial glutamate transporter, pres-
ent in the neonatal period with intractable myoclonic seizures
with burst suppression on the EEG and low amplitude visual
evoked potentials.43 The ERG may also be abnormal. Serial
MRI shows brain atrophy. Mitochondrial oxidation of gluta-
mate is impaired but there is no readily available metabolite or
enzyme test to facilitate diagnosis of this disorder. Muscle
biopsy is needed to diagnose other mitochondrial epilepsies
presenting in the neonatal period, as discussed by Rahman
(2012).4
Within the past 2 years, three disorders have been described
that affect the synthesis of lipoic acid or its incorporation into
mitochondrial enzymes (pyruvate dehydrogenase, a-ketogluta-
rate dehydrogenase, and the glycine cleavage enzyme). One of
these disorders, lipoic acid synthetase deficiency presented
with neonatal seizures (which were unilateral, associated with
oral automatisms and initially controlled with phenobarbi-
tone) and hypotonia, followed by progressive encephalopathy
and apnoea. Blood lactate and plasma glycine were elevated.
Proteins which are normally lipoylated showed reduction in
incorporation of the prosthetic group.44
Review 29
Disorders of protein O-glycosylation
The dystroglycanopathies can present in the newborn period
with congenital muscular dystrophy (weakness, hypotonia, and
moderately elevated creatine kinase), seizures, and ocular
abnormalities. Imaging may show lissencephaly and other
brain malformations. The diagnosis is usually made by muscle
biopsy.
Adenylosuccinate lyase deficiency
This disorder of purine metabolism (OMIM 608222) can
present in the neonatal period with severe seizures and
hypotonia. An affected infant may also show signs of intrauter-
ine growth retardation and microcephaly. Diagnosis depends
on the identification of abnormal purine metabolites in the
urine.
Cathepsin D deficiency
Cathepsin D deficiency (OMIM 610127) has been reported in
two families with congenital neuronal ceroid lipofuscinosis
(NCL), presenting with microcephaly and intractable
seizures,45 and in another child, who presented at school
age.46 Affected infants with the congenital disorder presented
with microcephaly from birth (with a history of deceleration
of head growth in the last trimester and abnormal fetal
movements suggestive of in utero seizures), and intractable
neonatal seizures leading to death by 10 days of age. Diagnosis
involves demonstration of abnormal storage material, assay of
cathepsin D, and mutation analysis of the CTSD gene. Cur-
rently there are no effective treatments for cathepsin D defi-
ciency, or for any of the NCL disorders.
GABA transaminase deficiency
4-Aminobutyrate aminotransferase (GABA transaminase) defi-
ciency (OMIM 613163) is a rare cause of neonatal-onset sei-
zures and has been reported in three families to date.47–49
Consistent clinical features are intractable seizures, severe psy-
chomotor retardation, hypotonia, hyperreflexia, and acceler-
ated linear growth. A spongy leukodystrophy was observed in
two individuals in whom neuropathology was performed.
Diagnosis can be made by demonstrating elevated levels of
GABA in the CSF or on proton magnetic resonance spectro-
scopy of the brain; by enzyme assay in cultured lymphocytes;
and by molecular analysis of the responsible gene ABAT.
There is no effective treatment.
METABOLIC EPILEPSY PRESENTING IN LATE
INFANCY AND EARLY CHILDHOOD
Treatable disorders
Disorders of creatine biosynthesis and transport
Three disorders of creatine metabolism have been described:
guanidinoacetate methyl transferase (GAMT) deficiency
(OMIM 612736) and arginine–glycine amidinotransferase
deficiency (OMIM 612718), both of which are recessively
inherited, and the X-linked cerebral creatine transporter defect
(OMIM 300352). All may be associated with epilepsy, but
seizures are most prominent in GAMT deficiency. This is
probably because two disease mechanisms are at play in
GAMT deficiency: cerebral energy deficiency (in common
with arginine–glycine amidinotransferase and creatine trans-
porter deficiencies) but also a direct neurotoxic effect of
guanidinoacetate, the accumulating metabolite in GAMT
deficiency.50 Seizures occur in over 90% of patients with
GAMT deficiency, and are typically of multiple types includ-
ing myoclonic, generalized tonic–clonic, partial complex, head
nodding, and drop attacks.51 Diagnosis may be achieved by
demonstrating low cerebral creatine levels on magnetic reso-
nance spectroscopy; by measuring guanidinoacetate, creatine,
and creatinine levels in plasma and urine; and by molecular
analysis of the three responsible genes (GAMT, GATM, and
SLC6A8 for the GAMT, arginine–glycine amidinotransferase,
and transporter defects respectively). Treatment with oral
creatine monohydrate is sufficient to restore cerebral creatine
levels, but dietary arginine restriction is additionally required
in GAMT deficiency to reduce guanidinoacetate accumulation.
Recent studies have indicated that ornithine supplementation,
in addition to creatine supplementation and arginine restric-
tion, improves clinical outcomes in GAMT deficiency.52
Cerebral folate deficiency
Several disorders of folate metabolism and transport have been
reported,53 often associated with megaloblastic anaemia
and ⁄or hyperhomocystinaemia. Recently, two defects of folate
metabolism have been shown to cause prominent seizures.
Mutations in the FOLR1 gene encoding the folate receptor a
(OMIM 613068), the major folate transporter across the
blood–CSF barrier, have been reported in four families.54–56
Patients presented with progressive ataxia and seizures (myo-
clonic epilepsy and generalized tonic–clonic seizures) in the
second year of life. Deficiency of dihydrofolate reductase
(OMIM 613839), the enzyme responsible for catalysing the
conversion of dihydrofolate to tetrahydrofolate, causes cere-
bral folate deficiency with generalized tonic–clonic and focal
seizures and megaloblastic anaemia or pancytopenia.57,58 Both
the folate receptor a and deficiencies of dihydrofolate
reductase are associated with virtually undetectable levels of 5-
methyltetrahydrofolate in CSF, and clinical and biochemical
responsiveness to oral folinic acid supplementation. Cerebral
folate deficiency has also been linked to the presence of
autoantibodies against the folate receptor in CSF, and may
occur as a secondary phenomenon in other IEMs including
disorders of serine biosynthesis and mitochondrial disorders,
particularly Kearns–Sayre syndrome caused by single mito-
chondrial DNA (mtDNA) deletions.59
Disorders of coenzyme Q10 biosynthesis
Disorders of CoQ10 biosynthesis represent the most treatable
mitochondrial disorders. Many present in infancy with a
multisystem syndrome including epilepsy, frequently associ-
ated with sensorineural hearing loss and a prominent steroid-
resistant nephropathy. Other neurological features in these
patients include nystagmus, ataxia, spasticity, and dystonia.
Mutations in five genes (COQ2, PDSS1, PDSS2, COQ9, and
COQ6) have so far been reported to cause infantile onset of
CoQ10 deficiency.
60 Treatment is with oral CoQ10 supple-
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mentation; 10 to 30 mg ⁄kg ⁄day in three divided doses is usu-
ally sufficient. The best outcome in this disorder was reported
in a female who was diagnosed early because of an affected
older sibling, and in whom treatment was initiated at the first
manifestation of disease.61
Pyruvate dehydrogenase deficiency
Males with the X-linked form of pyruvate dehydrogenase
complex (PDHc) deficiency usually present with Leigh syn-
drome (OMIM 308930), but females who are heterozygous
for a severe mutation in the PDHA1 gene can present in the
first 6 months of life with infantile spasms, an EEG showing
hypsarrhythmia, and developmental regression (West syn-
drome), or just with severe myoclonic seizures (OMIM
312170). MRI may show periventricular multicystic leukoen-
cephalopathy and agenesis of the corpus callosum. CSF lactate
is often elevated, usually with an elevation of blood lactate,
and fibroblast studies show reduced pyruvate dehydrogenase
complex activity. Some cases of pyruvate dehydrogenase
complex deficiency respond well to treatment with thiamine
and ⁄or a ketogenic diet, and this response can include a
reduction in seizure severity.62
Peroxisomal disorders
In males with X-linked adrenoleukodystrophy (OMIM
300100), other problems usually become evident before
epilepsy: changes in behaviour, perceptive, and intellectual
difficulties, expressive and motor difficulties, and visual distur-
bances. However, in one large series, 20 out of 485 individuals
presented with seizures: focal seizures in six males and general-
ized in the remainder, with four having status epilepticus.63 A
careful history may identify symptoms attributable to adrenal
insufficiency such as weakness and tiredness, anorexia, vomit-
ing with diarrhoea or constipation, and crises with abdominal
pain, vomiting, and dehydration, and examination may reveal
pigmentation of mucous membranes. The disorder is caused
by mutations in the ABCD1 gene, which impair peroxisomal
b-oxidation, resulting in the accumulation of very long-chain
fatty acids in plasma. It has been suggested that presymptom-
atic patients may benefit from early intake of oleic and erucic
acids (combined in a 4:1 ratio in Lorenzo’s oil) in addition to
very long-chain fatty acid restriction,64 but this has not been
confirmed in other studies. Adrenal hormone replacement is
necessary in all patients with adrenal insufficiency. Haemato-
poietic stem cell transplantation should be considered in males
who develop MRI abnormalities, since this treatment can
arrest the cerebral demyelination.65 Haematopoietic stem cell
transplantation is not carried out routinely in all presymptom-
atic cases, since some affected individuals may never develop
progressive cerebral disease. Serial brain MRI is therefore
extremely important in determining the need for and optimal
timing of haematopoietic stem cell transplantation.
Hyperprolinaemia type II
This disorder (OMIM 239510) results from a deficiency of
D1-pyrroline 5-carboxylate dehydrogenase and is character-
ized by elevated plasma proline and increased urinary excre-
tion of proline, hydroxyproline, and glycine. It is the
accumulation of pyrroline 5-carboxylate which adducts with
PLP that is thought to lead to vitamin B6 deficiency,66 a
mechanism analogous to that of PLP with D1-piperideine-
6-carboxylate in antiquitin deficiency (see above). Clinically,
hyperprolinaemia type II is characterized by seizures that are
usually precipitated by infection and fever. In at least one
reported case, seizures have shown a good response to pyri-
doxine.67
Phenylketonuria
Seizures used to occur in infants with phenylketonuria
(OMIM 261600) before diagnosis by neonatal screening and
early institution of a low-phenylalanine diet. In children from
developing countries who have not been part of a comprehen-
sive newborn screening programme, phenylketonuria should
still be considered as a possible cause of seizures, particularly if
accompanied by developmental delay.
Cerebral organic acidurias
There are some disorders that can be diagnosed by analysis of
urine organic acids and ⁄or blood spot acylcarnitines in which
seizures can occur without preceding signs of acute encepha-
lopathy and without evidence of acidosis, hyperammonaemia,
and so on. These include methylmalonic aciduria due to
cobalamin defects (e.g. cobalamin C disorder; OMIM 277400)
for which there are specific treatments, such as a high dose of
vitamin B12 and betaine, that may be able to help with seizure
control; 4-hydroxybutyric aciduria (succinic semialdehyde
dehydrogenase deficiency; OMIM 271980), for which vigaba-
trin may be beneficial; L-2-hydroxyglutaric aciduria (OMIM
600721), for which treatment with riboflavin (with or without
L-carnitine) has been shown to improve cognitive and motor
performance;68,69 D-2-hydroxyglutaric aciduria (OMIM
236792) for which no successful treatment has been described;
and 3-hydoxyisobutyryl-CoA hydrolase deficiency (OMIM
250620), which can be suspected on the basis of increased
hydroxy-C4 carnitine in the blood spot and in which progres-
sion of neurological disease has been arrested by treatment
with L-carnitine, dietary valine restriction, N-acetylcysteine,
and antioxidants (unpublished observation).
Other disorders
Infantile and late infantile neuronal ceroid lipofuscinosis
NCLs are a group of autosomal recessive progressive neurode-
generative disorders clinically characterized by the triad of epi-
lepsy, developmental regression ⁄dementia, and pigmentary
retinopathy. More than 10 genetic defects have been linked to
the NCLs, most with characteristic ages at onset.50 All except
infantile NCL (NCL type 1) are characterized by progressive
myoclonus. Neuronal ceroid lipofuscinosis type 1 presents
with developmental delay or arrest towards the end of the first
year of life. Seizures are infrequent and myoclonus may be seen
as only isolated jerks. By contrast, in the late infantile form
(NCL type 2), myoclonus and tonic–clonic seizures are early
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and frequent with onset from 2 to 4 years. Neurophysiology
features can be very helpful in indicating the diagnoses in
NCLs, including progressive loss of EEG activity and ERG in
NCL type 1 and abnormal enlarged visual and somatosensory
evoked potentials and posterior paroxysms triggered by photic
stimulation in NCL type 2.
Diagnosis rests on assay of enzyme activity (palmitoyl pro-
tein thioesterase and tripeptidyl thioesterase) in dried blood
spots, followed by molecular analysis of the CLN1 and CLN2
genes. Rare cases are not caused by mutations in these two
genes, and further investigation will necessitate electron
microscopic examination of skin or rectal biopsies to search
for characteristic inclusion bodies. If these are demonstrated,
sequence analysis of the CLN5, -6, -7, and -8 genes should be
performed.
Gangliosidoses
Infants with infantile GM1 gangliosidosis (OMIM 230500)
are often hypotonic from birth and stop making develop-
mental progress at 3 to 6 months of age. Examination will
reveal coarsening of facial features, and usually hep-
ato(spleno) megaly. Many have a cherry-red spot at the
macula, and radiology often shows dysostosis. Seizures are a
major part of the progressive neurological dysfunction. GM2
gangliosidosis (Tay–Sachs disease; OMIM 272800) presents
at 4 to 6 months with motor weakness, hypotonia, and a
typical startle response to sound (auditory myoclonus). Pro-
gressive loss of milestones, hypotonia, and visual inattentive-
ness follow. A cherry-red spot is almost always present.
Seizures and spasticity characterize the final phase of the ill-
ness. Myoclonic seizures are common, and can be massive
and multiple. Focal, generalized, and occasionally gelastic
seizures also occur.
Alpers syndrome and other infantile-onset mitochondrial
disorders
Alpers syndrome (progressive neuronal degeneration of chil-
dhood with liver disease; OMIM 203700) typically presents in
late infancy with intractable seizures, which may initially be
focal and subsequently generalize.70 Epilepsia partialis con-
tinua and convulsive status epilepticus are common. A charac-
teristic and unusual EEG pattern of large-amplitude slow
activity with superimposed smaller multispike discharges may
be seen early on and then disappear as the disease progresses.
There may be an antecedent history of developmental delay
and associated liver dysfunction. The disorder is caused by
progressive depletion of the mtDNA, as a result of an underly-
ing recessively inherited defect of mtDNA replication, most
often because of defective DNA polymerase gamma function
resulting from POLG mutations, although occasionally the
responsible mutations may be in the PEO1 gene encoding the
Twinkle DNA helicase.71 The course is usually rapidly pro-
gressive; most affected infants die before the age of 3 years.
Treatment is supportive. Other mitochondrial disorders pre-
senting with epilepsy in infancy, including maternally inher-
ited Leigh syndrome, have been discussed in detail in a recent
review.4
Congenital disorders of protein N-glycosylation
More than 13 disorders affecting N-glycosylation have been
described, and the majority affect the CNS. They can present
with failure to thrive and multisystem disease in early infancy;
hypotonia and seizures can be part of the clinical picture. Sei-
zures can be a major presenting feature in an older infant.
They can be associated with hypotonia and ⁄or ataxia, suggest-
ing a diagnosis of cerebral palsy, but additional clinical fea-
tures can point the astute paediatrician to the correct
diagnosis; these include dysmorphic features such as unusual
fat pads on the buttocks, inverted nipples, long fingers and
toes, and craniofacial dysmorphic features. Diagnosis of most
of the disorders of protein N-glycosylation can be made by
isoelectric focusing of serum transferrin. There is no specific
form of treatment for the seizures associated with the disor-
ders of N-glycosylation.




Very few metabolic epilepsies presenting in late childhood and
adolescence are treatable; CoQ10 deficiency (OMIM 607426)
is a notable exception.60 Late-onset CoQ10 deficiency syn-
dromes are frequently associated with epilepsy, particularly
those caused by mutations in the ADCK3 (CABC1) gene.
Patients with ADCK3 mutations have a relatively homo-
geneous phenotype, with cerebellar ataxia and seizures, and a
favourable response to exogenous CoQ10 supplementa-
tion.72,73 Other patients with CoQ10 deficiency present with
recurrent rhabdomyolysis and an encephalomyopathy includ-




Progressive myoclonic epilepsies presenting in this age group
include Unverricht–Lundborg disease (Baltic myoclonus;
OMIM 254800), Lafora body disease (OMIM 254780), and
mitochondrial diseases such as MERRF (myoclonic epilepsy
with ragged-red fibres; OMIM 545000) syndrome, and disor-
ders related to mutations in the DNA polymerase gamma.
Unverricht–Lundborg disease is a Finnish heritage disorder
and occurs in approximately 1 in 20 000 of the Finnish popu-
lation. It has also been reported in other ethnic groups in
northern Europe and North America. Affected children are
normal in early childhood, and usually present with clonic or
tonic–clonic seizures followed by stimulus-sensitive, action-
triggered myoclonus between the ages of 6 and 16 years. Asso-
ciated clinical problems include ataxia and mild learning diffi-
culties. The diagnosis is confirmed by finding mutations in the
EPM1 gene encoding cystatin B.75 Severity and disease
progression vary between and within families. The disease is
associated with severe disability but is not usually life-limiting.
Phenytoin is contraindicated in this condition since it may
exacerbate the seizures.
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Lafora body disease presents in the same age group (6–18y)
but is more rapidly progressive. Affected individuals are often
bed bound and require almost constant rest, exhibit action-
triggered myoclonus, and develop severe dementia within 5 to
10 years of disease onset. Visual seizures may be a feature.
Convulsive status epilepticus often precipitates death. The
diagnosis may be suspected by the identification of Lafora
bodies (polyglucosan inclusion bodies) in neurons in a
full-thickness skin biopsy. Eighty per cent of affected individu-
als have mutations in the EPM2A gene encoding laforin,
whereas approximately 20% have mutations in NHLRC1,
encoding malin. No genetic defect is identified in a minority
of cases.75
Mitochondrial epilepsies
Several mitochondrial disorders may present with seizures in
late childhood and adolescence.4 MERRF syndrome is usually
caused by a maternally inherited mtDNA mutation, most
often the m.8344A>G mutation in the gene encoding the
transfer RNA for lysine. Recessive POLG mutations typically
cause Alpers syndrome (see above) or other infantile-onset
mtDNA depletion syndromes, but may also present in adoles-
cence with progressive epilepsy mimicking MERRF
syndrome. Several acronyms have been coined for these late-
onset recessive POLG disorders associated with epilepsy,
including MIRAS (mitochondrial recessive ataxia syndrome),
SCAE (spinocerebellar ataxia with epilepsy; OMIM 607459),
and MEMSA (myoclonus, epilepsy, myopathy, sensory ataxia),
but these probably represent a disease continuum. Patients
with MELAS (mitochondrial encephalomyopathy, lactic
acidosis, stroke-like episodes; OMIM 540000) syndrome typi-
cally present towards the end of the first decade of life with a
stroke-like episode which may be heralded by focal seizures,
migrainous headache, and vomiting. Eighty per cent of
patients with MELAS have the same genetic cause: the
m.3243A>G mutation in the gene encoding the transfer RNA
for leucineUUR.
Lysosomal storage disorders
In juvenile NCL (Batten’s disease; OMIM 204200), retinopa-
thy is usually the presenting symptom, whilst epilepsy and
dementia typically occur late in the disease course. The triad
of clinical features (retinopathy, epilepsy, and dementia),
together with the presence of vacuolated lymphocytes in the
peripheral blood film, may suggest the diagnosis, which is con-
firmed by mutation analysis of the CLN3 gene. Absence sei-
zures may be more frequent than tonic–clonic seizures.
Myoclonus particularly affects the face.
In subacute ⁄chronic neuronopathic Gaucher disease (Gau-
cher type III; OMIM 231000) neurological symptoms with
evidence of systemic disease (e.g. splenomegaly) typically
occur at a mean age of 10 years. One neurological phenotype
is characterized by progressive myoclonic encephalopathy with
seizures and dementia. In some cases this is preceded by supra-
nuclear gaze palsy, and there may be an extrapyramidal move-
ment disorder. As in juvenile NCL, facial myoclonus is a
feature.
Type I sialidosis (neuraminidase deficiency; OMIM
256550) often presents in the second or third decade with pro-
gressive visual handicap with impaired colour vision and ⁄or
night blindness; a cherry-red spot is typically present at the
macula. Severe myoclonic epilepsy follows in almost 50% of
cases, leading to the name ‘cherry-red spot myoclonus syn-
drome’. Seizures are often difficult to control.
Niemann–Pick type C (NPC; OMIM 257220) is a disor-
der of lysosomal cholesterol export with secondary accumu-
lation of sphingomyelin. Although the disease most often
presents in the first 2 years of life, late-onset forms present-
ing with epilepsy (partial, generalized tonic–clonic, and ato-
nic seizures) are recognized. Hepatosplenomegaly and
vertical supranuclear gaze palsy may provide clues to the
underlying diagnosis, which may be tricky to establish.
Abnormal storage cells (sea-blue histiocytes) may be
observed in the bone marrow and filipin staining of cultured
skin fibroblasts may demonstrate lipid accumulation.
Approximately 95% of cases have mutations in the NPC1
gene and 5% in NPC2. There is no curative treatment for
Niemann–Pick type C but recently a glycosphingolipid syn-
thesis (glucosylceramide synthase) inhibitor was approved for
the treatment of this condition, based on evidence from a
randomized controlled trial that showed stabilization ⁄ slow-
ing of neurological progression.76
Peroxisomal disorders
Alpha methyl-acyl-CoA racemase deficiency can produce a
wide range of neurological problems with onset in childhood
or adult life. These include developmental delay, epilepsy,
acute encephalopathy, tremor, pigmentary retinopathy, hemi-
paresis, spastic paraparesis, peripheral neuropathy, depression,
headache, and cognitive decline. One female presented at age
13 with epilepsy and a postictal confusional state and had no
further symptoms for 5 years.77 Elevation of plasma pristanic
acid is a diagnostic clue.
APPROACH TO DIAGNOSIS
The differential diagnosis of seizure disorders is extremely
wide and includes ion channel disorders (e.g. SCN1A muta-
tions), malformations of cortical development, neurocutane-
ous syndromes, chromosomal disorders, hypoxic–ischaemic
encephalopathy, congenital infection, sepsis, and tumours.
However, certain features in the history and clinical examina-
tion may lead to suspicion of an underlying inborn error of
metabolism. These include parental consanguinity, a similarly
affected sibling, and a history of in utero ‘hiccoughs’ or ‘flut-
tering’ movements, which might represent antenatal seizures.
Seizures occurring after fasting are suggestive of hypoglyca-
emia or neuroglycopaenia.
The combination of particular facial features (large fonta-
nelle, high forehead, flat occiput, and shallow supraorbital
ridges) with seizures may raise suspicion of a peroxisomal dis-
order, particularly Zellweger syndrome. A macular cherry-red
spot on fundoscopy, or vacuolated lymphocytes in the periph-
eral blood film, indicate a lysosomal storage disorder. In other
patients there may be characteristic abnormalities of the skin
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and ⁄or hair. For example, in Menkes syndrome defective
keratinization of the hair leads to sparseness and a ‘kinky’
appearance caused by the formation of pili torti. Patients with
Menkes syndrome also have typical facies and may have con-
nective tissue and bone abnormalities, as well as severe devel-
opmental delay and epilepsy. Children with biotinidase
deficiency may present with an eczematous rash, particularly
affecting the periorbital and perioral areas, together with alo-
pecia. They may also have optic atrophy and sensorineural
hearing loss, particularly if diagnosed late. Multisystem disease
features may raise suspicion of a mitochondrial disorder.
For example, the combination of steroid-resistant nephrotic
syndrome, sensorineural hearing loss, ataxia, and seizures is
suggestive of CoQ10 deficiency.
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Althoughneither seizure type norEEGappearance is specific
for particular IEMs, an underlying metabolic disorder should
be considered in children with myoclonic seizures, intractable
seizures resistant to multiple AEDs, epileptic encephalopathy,
and those with a burst suppression EEGpattern. Burst suppres-
sion is typically seen early in the disease course in several early-
onset metabolic epilepsy syndromes, including non-ketotic hy-
perglycinaemia, pyridoxine-dependent epilepsy, PNPO defi-
ciency, defects of the mitochondrial glutamate transporter
SLC25A22, and SUOX and MoCoF deficiencies, but is also a
feature of many non-metabolic epilepsy syndromes. In Alpers
syndrome there may initially be characteristic EEG changes
(rhythmic high-amplitude delta waves with superimposed
[poly]spikes over parieto-occipital regions), but later in the dis-
ease courseEEGabnormalities tend to generalize.70
Brain MRI usually reveals non-specific changes only. How-
ever, in occasional cases, brain MRI may be diagnostic: for
example, children with pontocerebellar hypoplasia visible on
MRI that is associated with intractable seizures and develop-
mental stasis may have RARS2 mutations, a disorder of mito-
chondrial translation.42 In other conditions MRI may be
suggestive but not diagnostic; for example, cystic degeneration
may be observed in SUOX andMoCoF deficiencies. Magnetic
resonance spectroscopy is essential for the diagnosis of the cre-
atine transporter disorder, since urinary levels of creatine
metabolites may be normal in this condition.
The mainstay of diagnosis of IEMs is of course biochemical
investigation. Metabolites may be assayed in blood, urine, or
CSF (Table II). Where specific enzyme assays are available,
these have been described in the appropriate sections above.
Genetic diagnosis is increasingly available for IEMs, and con-
stitutes the first line of investigation in rare instances where
there are no characteristic metabolites or diagnostic enzyme
assay, such as mutation analysis of SLC25A22 for mitochon-
drial glutamate transporter deficiency. Increased availability
and ease of genetic testing is leading to expansion of the
epileptic phenotypes of many of the genetic and indeed the
metabolic epilepsies, with GLUT1 and serine disorders being
more recent examples.
TREATMENT
Specific treatments, where available, have been described in
the main text above, and are summarized in Table III.
CONCLUSIONS
IEMs are a relatively rare cause of epilepsy, but their recogni-
tion and diagnosis is important because several disorders are
treatable, often with simple therapies such as vitamins. Prompt
treatment can affect long-term neurological outcome, there-
fore diagnosis should not be delayed. Associated clinical, bio-
chemical, and imaging features may provide clues to the
underlying diagnosis.
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Table III: Treatment of metabolic epilepsies
Disorder Treatment
Established therapies
Pyridoxine-dependent epilepsy Pyridoxine 100mg i.v. initial dose followed by 5–10mg ⁄ kg ⁄d p.o.,
maximum 200mg per day
PNPO deficiency Pyridoxal 5¢-phosphate 10–30mg ⁄ kg ⁄d p.o.
Biotinidase deficiency Biotin 5–10mg ⁄d p.o.
Holocarboxylase synthetase deficiency Biotin 10–20(40)mg ⁄d p.o.
GLUT1 defect Ketogenic diet
Disorders of creatine biosynthesis and transport Creatine 350–500mg ⁄ kg ⁄d p.o. Arginine restriction in GAMT
deficiency (15–25mg ⁄ kg ⁄d; corresponds to 0.4–0.7 g ⁄ kg ⁄d protein intake)
Dihydrofolate reductase deficiency Folinic acid 30mg ⁄d p.o.
Folate receptor defect Folinic acid 5mg ⁄ kg ⁄d p.o.54
Disorders of serine biosynthesis L-Serine 200–600mg ⁄ kg ⁄d p.o.; if seizures continue add glycine 200mg ⁄ kg ⁄d p.o.
Disorders of CoQ10 biosynthesis CoQ10 10–30mg ⁄ kg ⁄d p.o. in children; 1200–3000mg ⁄d in adults
Experimental therapies
Menkes syndrome Copper injections (early diagnosed cases only)
Molybdenum cofactor deficiency (MOCS1) Cyclic pyranopterin
Non-ketotic hyperglycinaemia Benzoate, dextromethorphan, folinic acid
GAMT deficiency Ornithine supplementation
i.v., intravenous; p.o., per os; PNPO, pyridox(am)ine 5¢-phosphate oxidase; GLUT1, glucose transporter across the blood–brain barrier; GAMT,
guanidinoacetate methyl transferase; CoQ10, coenzyme Q10; MOCS1, molybdenum cofactor synthesis gene 1.
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ONLINE RESOURCES
It has not been possible to provide a detailed discussion of all the met-
abolic epilepsies mentioned in this review, owing to space constraints;
the reader is referred to the database Online Mendelian Inheritance
in Man (http://www.omim.org) for further information. OMIM num-
bers have been indicated throughout the text. Further information
may also be found in The Online Metabolic and Molecular Bases of
Inherited Diseases (http://www.ommbid.com).
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